The company said its total revenues for Q3 2026 rose to $13,069 million from $12,222 million a year earlier, an increase of 7%. Growth Portfolio revenues increased 12% to $7.7 billion, and Legacy Portfolio revenues increased 1% to $5.4 billion.

1. 01

   The company said its total revenues for Q3 2026 rose to $13,069 million from $12,222 million a year earlier, an increase of 7%. Growth Portfolio revenues increased 12% to $7.7 billion, and Legacy Portfolio revenues increased 1% to $5.4 billion.

2. 02

   Bristol Myers Squibb said GAAP EPS for Q3 2026 was $1.05 ($1.08 a year earlier), and non-GAAP EPS was $1.35 ($1.63 a year earlier). Both figures include the net impact of Acquired IPRD charges and licensing income of $(0.58).

3. 03

   The company said GAAP gross margin for Q3 fell to 68.3% from 71.9%, mainly reflecting a change in product mix. Acquired IPRD charges were $1,558 million, up from $633 million a year earlier.

4. 04

   The company said it raised its full-year 2026 non-GAAP revenue guidance to approximately $49.75 billion to $50.25 billion from approximately $49.0 billion to $50.0 billion. Its non-GAAP diluted EPS guidance changed to $6.35 to $6.55 from $6.75 to $7.00.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.